Lighthouse Pharmaceuticals, Inc. — SEC Form D Filing

Lighthouse Pharmaceuticals, Inc. filed an SEC Form D on May 7, 2026, reporting $15.21M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
May 7, 2026
Amount reported
$15.21M
Round stage
Series A
Industry
Pharmaceuticals
Website
https://www.lighthousepharma.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Patients with Alzheimer's disease associated with P. gingivalis face major unmet medical needs due to inadequate current treatments.

Solution

Lighthouse Pharmaceuticals is developing LHP588, a next-generation gingipain inhibitor targeting P. gingivalis-positive Alzheimer's disease.

Why now

There is a growing demand for innovative treatments in Alzheimer’s disease, especially for subtypes that are currently under-addressed.

Verdict

Investors backed Lighthouse Pharmaceuticals because the focus on a specific unmet need in Alzheimer's treatment presented a clear narrative, not because the competitive landscape was free from significant players. The implicit bet was on the therapeutic promise of LHP588 as a novel intervention against an emerging understanding of disease pathology. However, the limited upside lies in the crowded and competitive biopharma space, where established names dominate, putting pressure on long-term market penetration and differentiation.

Source: SEC EDGAR Form D filing